Hi readers,
How is your 2026 going so far?
It may only be the beginning of the year, but Feline Business Brief has been busier than ever (and not just because our in-house cats, Morag and Ethel, get their booster shots this time of year).
We’ve been tracking several feline market patterns that have really started to crystallise over the past several months:
Regulatory progress in feline therapeutics is advancing. Feline chronic diseases that were previously managed only indirectly (or not at all) are becoming part of formal treatment pathways, thanks to key regulatory approvals. For example, the FDA’s conditional approval of Felycin-CA1 for hypertrophic cardiomyopathy (HCM), one of the least treatable major feline diseases.
More brands are entering the cat category for the first time. In food, supplements and other sectors, cats are no longer treated as a secondary extension of dog strategies, but as a distinct commercial opportunity.
Hardware is increasingly functioning as a health tool. Feeders, litter boxes and monitoring devices are increasingly positioned as preventive health monitors, which in turn impacts how feline health data is generated and used.
Overall, these developments (and others) point to a broader shift in the feline economy. We explore these themes in depth in upcoming Feline Business Monitor (Q1) which launches next week.
In addition, the news cycle has also started picking up again! Read on to see this week’s cat-related headlines.
This week in cats:
USA
United Kingdom
Japan
LIke to advertise your brand or product in Feline Business Brief? Just click here.
Enjoying this article? Subscribe below to receive Feline Business Brief directly in your inbox.